Is Cabotegravir a Gender-Neutral PrEP Medication?
Alex Rinehart, PhD, explains how cabotegravir is a gender-neutral pre-exposure prophylaxis medication.
Alex Rinehart, PhD, Director, Global Prevention Strategy, ViiV Healthcare, explains studies that are underway involving how effective the PrEP medication cabotegravir is in men who have sex with men as well as transgendered women. Dr. Rinehart stresses that he and his team are trying to study efficacy in all relevant key populations affected by HIV.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Recent Videos
A Psychiatrist’s View on the Immune-Brain Connection
An Education Opportunity for Transplant and Oncology Infections
New Antifungal Drug Olorofim Shows Efficacy in Treating Resistant Fungal Infections
Improving Quality of Life For Those With Recurrent C Difficile
How Can Scientists and Investigators Find Funding Today?
A Pioneer in Coronavirus Research
Considering the Impact of Crop Spraying and Antifungal Resistance
Psychiatric Symptoms Emerging Years After Infections Like Lyme and Tick-Borne Infections
Deciphering Similarities and Differences in Antifungal and Antibiotic Development
Fidaxomicin Tied to Lower C difficile Recurrence in Immunocompromised Patients
Related Content
